Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting
2024-03-07
临床1期免疫疗法AACR会议细胞疗法
Company will also present new preclinical data for its orthoIL-2 technology for cytokine-inducible cell therapies
MENLO PARK, Calif.--(BUSINESS WIRE)-- Synthekine Inc., an engineered cytokine therapeutics company, today announced that data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonistIL-2 partial agonist, STK-012, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, from April 5-10, 2024. The company will also present new preclinical data for its orthogonal IL-2 (orthoIL-2) technology for cytokine-inducible cell therapies, currently being investigated in a Phase 1 study with the STK-009 + SYNCAR-001 combination therapy.
“AACR marks the first time Synthekine will present clinical data from the ongoing trial of STK-012, our lead program and a novel approach to biasing IL-2,” said Debanjan Ray, chief executive officer of Synthekine. “We are also excited to share new preclinical data with our orthoIL-2 technology comparing it head-to-head with other armoring approaches for CAR T-cell therapies. We look forward to sharing these results with the scientific community, while continuing our rapid progress to advance our broad pipeline of cytokine programs, including cytokine-inducible cell therapies, for the treatment of cancer, inflammatory and autoimmune diseases.”
Details are as follows and available on the AACR online itinerary planner:
Title: Initial results from a Phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonistIL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
Session Title: First-in-Human Phase I Clinical Trials 2
Session Date & Time: Tuesday, Apr 9, 2024, 9:00 AM – 12:30 PM PT
Location: Poster Section 48
Poster Board Number: 11
Abstract Number: CT183
Title: Orthogonal IL-2/IL-2Rβ signaling selectively enhances and sustains a synthetic effector state via a novel mechanism and outperforms constitutive armoring approaches
Session Title: Adoptive Cellular Therapy 2
Session Date & Time: Tuesday, Apr 9, 2024, 1:30 PM – 5:00 PM PT
Location: Poster Section 40
Poster Board Number: 3
Abstract Number: 6312
Copies of the posters will be available on Synthekine’s website following presentation at the meeting.
About Synthekine
Synthekine is harnessing the potential of cytokine therapeutics to develop selective immunotherapies designed to improve the treatment paradigm of cancer and inflammatory disease. Using insights on cytokine structure and function, the company engineers therapeutics designed to unlock the full efficacy potential of cytokines while avoiding their associated toxicities. Synthekine is applying principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms to create a broad and deep pipeline of product candidates. These novel immunotherapies include modified cytokines, cytokine-enhanced cell therapies and surrogate cytokine agonists. For more information, visit , and follow us on X @synthekine and LinkedIn.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。